We develop immune therapies that support the treatment and prevention of infectious disease and cancer

We develop immune therapies that directly stimulate a powerful immune response in the liver

Our lead programme is targeting a cure for the 250 million patients infected with chronic hepatitis B

Hepatitis B virus infection

Despite the availability of preventative vaccines, 2 billion people worldwide have been infected with hepatitis B virus (HBV). Over 250 million of those infected progress to chronic HBV infection and become susceptible to life threatening liver disease.  Avalia’s therapy aims to provide a necessary cure for these individuals.

Read More
>

Pipeline

Avalia’s immune therapies are designed to target the liver and spleen to modulate a more potent and targeted immune response against certain viruses and cancers. This is achieved by activating a special family of immune cells called natural killer T cells.

Read More
>

News

Key to a Cure

Avalia Immunotherapies could hold the key to a cure for chronic hepatitis B infection—a currently incurable, life-threatening liver disease that affects 250 million patients worldwide.

Read More
>

Harnessing the immune system

Avalia's founding CSO and head of  cancer immunotherapy at Malaghan Institute of Medical Research, Professor Ian Hermans, discusses the developing field of immunotherapy, and how we can use the knowledge gained from understanding the immune system to fight diseases such as…

Read More
>

Avalia receives NZ Innovation Award

And the 2017 winner of the Innovation Excellence in Research is... Avalia Immunotherapies!

Read More
>

National portrait – Richard Fureaux, pioneering chemist

Avalia congratulates one of its founding directors and now science advisor, Richard Furneaux, for his huge contribution to biotech research and success in leading the second only Kiwi team to get a drug to market.

Read More
>

Five-year research partnership

Avalia's research partner, the Ferrier Research Institute at Victoria University of Wellington continues to pioneer new ground with Avalia's NKT cell agonist vaccines.

Read More
>